Earlier this summer, we put a call out to the Parkinson’s community across Canada to have your say about apomorphine (brand name Movapo®) and treatment options for people with Parkinson’s.

Thanks to your timely and meaningful input, we were able to prepare a patient evidence submission to CADTH, the Canadian Agency for Drugs and Technologies in Health.

We will keep you informed as any major milestones are reached. If you wish to follow the progress of this review now that together we completed the first important step, visit the CADTH website page that outlines the next steps in this review process: https://www.cadth.ca/apomorphine

The final recommendation is expected early in January 2018. If there is a positive recommendation, further processes will need to get underway before public coverage is made available. We will be sure to keep you informed.

We are grateful for your input and we are here if you have any follow-up questions. Contact Jacquie.Micallef@parkinson.ca.